



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Mustapha Haddach et al.
 Application No. : 10/785,386
 Filed : February 23, 2004
 For : CRF RECEPTOR ANTAGONISTS AND METHODS
 RELATING THERETO

Art Unit : 1614
 Docket No. : 690068.459C4
 Date : July 15, 2004

Mail Stop Missing Parts
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:


In accordance with 37 CFR 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached Form PTO-1449. This application relies, under 35 U.S.C. § 120, on the earlier filing date of prior Application No. 10/027,789, filed December 20, 2001, now U.S. Patent 6,723,721, which is a continuation of prior Application No. 09/439,841, filed November 12, 1999, now U.S. Patent 6,348,466, which is a continuation-in-part of prior Application No. 09/400,744, filed September 21, 1999, now abandoned, which is a continuation-in-part of prior Application No. 09/190,958, filed November 12, 1998, now abandoned. The references listed on the attached Forms PTO-1449 were submitted to and/or cited by the Patent and Trademark Office in these prior applications and, therefore, are not required to be provided in this application. If the Examiner wishes, copies will be provided upon request. As to any reference made of record on the attached form PTO-1449, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 CFR 1.131 or other method. Although the aforesaid references are made known to the

Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Applicants believe this Information Disclosure Statement has been timely filed, however, the Director is authorized to charge any fee due by way of this Information Disclosure Statement to our Deposit Account No. 19-1090.

Respectfully submitted,
Seed Intellectual Property Law Group PLLC



Karl R. Hermanns
Registration No. 33,507

Enclosures:
Form PTO-1449

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

496833

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
690068.459C4APPLICATION NO.
10/785,386**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

APPLICANTS
Mustapha Haddach et al.FILING DATE
February 23, 2004GROUP ART UNIT
1614**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	4,605,642	08/12/86	Rivier et al.	514	12	
	AB	4,904,658	02/27/90	Tseng et al.	514	233.2	
	AC	5,063,245	11/05/91	Abreu et al.	514	404	
	AD	5,464,847	11/07/95	Courtemanche et al.	514	342	
	AE	5,880,135	03/09/99	Gully et al.	514	307	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AF	WO 94/13643	06/23/94	WIPO		
	AG	WO 94/13644	06/23/94	WIPO		
	AH	WO 94/13661	06/23/94	WIPO		
	AI	WO 94/13676	06/23/94	WIPO		
	AJ	WO 94/13677	06/23/94	WIPO		
	AK	WO 95/10506	04/20/95	WIPO		
	AL	WO 95/33750	12/14/95	WIPO		
	AM	WO 95/34563	12/21/95	WIPO		
	AN	WO 96/35689	11/14/96	WIPO		
	AO	WO 97/00868	01/09/97	WIPO		X


OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AP	De Souza et al., "Heterogeneity of Corticotropin Releasing Factor Receptors: Multiple Targets for the Treatment of CNS and Inflammatory Disorders," <i>Annual Reports in Medicinal Chemistry</i> 30:21-30, 1995.
	AQ	McCarthy et al., "Recent Progress in Corticotropin-Releasing Factor Receptor Agents," <i>Annual Reports in Medicinal Chemistry</i> 34:11-20, 1999.
	AR	Rivier et al., "Synthetic Competitive Antagonists of Corticotropin-Releasing Factor: Effect on ACTH Secretion in the Rat," <i>Science</i> 224: 889-891, 1984.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).



EXPRESS MAIL NO. EV335393221US

Sheet 2 of 2

FORM PTO-1449
(REV.7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
690068.459C4APPLICATION NO.
10/785,386**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

APPLICANTS

Mustapha Haddach et al.

FILING DATE

February 23, 2004

GROUP ART UNIT

1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA						
	BB						
	BC						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	BD	WO 97/35539	10/02/97	WIPO		
	BE	WO 97/35580	10/02/97	WIPO		
	BF	WO 97/35846	10/02/97	WIPO		
	BG	WO 97/44038	11/27/97	WIPO		
	BH	WO 98/03510	01/29/98	WIPO		
	BI	WO 98/05661	02/12/98	WIPO		
	BJ	WO 98/08846	03/05/98	WIPO		
	BK	WO 98/08847	03/05/98	WIPO		
	BL	WO 98/11075	03/19/98	WIPO		
	BM	WO 98/15543	04/16/98	WIPO		X
	BN	WO 98/21200	05/22/98	WIPO		
	BO	WO 98/29413	07/09/98	WIPO		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	BP	
	BQ	
	BR	

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).